Xiuming Liang

This study develops bioengineered extracellular vesicles that neutralize pneumolysin and reduce inflammation in pneumococcal meningitis, improving survival in a mouse model.

This paper demonstrates efficient genome editing in non-human primate brains using engineered extracellular vesicles, achieving therapeutic potential for neurological disorders.

This study develops an engineered extracellular vesicle platform that improves shRNA loading and delivery efficiency, achieving robust gene silencing in multiple cell types and the mouse brain.

This study shows that systemic inflammation significantly prolongs EV plasma half-life and enhances their accumulation in inflamed organs like the liver and spleen.

This study investigates the role of tetraspanins in EV bioengineering by knocking out CD9, CD63, and CD81 in HEK293T cells and shows increased engineered EV production upon reintroduction of tetraspanin-fusion constructs.

This paper develops intein-engineered virus-like particles for efficient gene editing delivery, achieving robust gene editing in multiple cell types and organs.

This paper develops a modular strategy for delivering CRISPR-Cas9 via extracellular vesicles using aptamer-based loading and UV-activated cargo release, demonstrating efficient delivery and versatility in Cas9 variants.

This paper develops hPep-based nanoparticles for efficient delivery of gene editors across multiple cell types, achieving high editing efficiency in human cells.

This paper develops a PTTG1IP-based platform for efficient extracellular vesicle (EV) cargo delivery, showing improved therapeutic delivery compared to CD63-based scaffolds.

The paper identifies 24 novel scaffold proteins with conserved EV-sorting abilities, outperforming CD63 in cargo loading and demonstrating improved EV engineering potential.